Tarsus Pharmaceuticals, Inc.
TARS
$40.81
$1.995.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 29.19% | 14.97% | -24.87% | -65.00% | -127.06% |
| Total Depreciation and Amortization | 35.67% | 39.68% | 81.53% | 130.13% | 168.81% |
| Total Amortization of Deferred Charges | 21.29% | 25.19% | 29.26% | 23.77% | 24.78% |
| Total Other Non-Cash Items | 31.03% | 60.27% | 79.44% | 87.47% | 58.36% |
| Change in Net Operating Assets | 253.04% | 1,156.21% | 111.51% | -85.79% | -72.37% |
| Cash from Operations | 50.58% | 29.33% | -12.52% | -64.57% | -139.28% |
| Capital Expenditure | -48.43% | -4.33% | 8.23% | -17.63% | -95.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -557.15% | -239.07% | -423.64% | -12.33% | 121.45% |
| Cash from Investing | -587.02% | -241.67% | -442.68% | -12.43% | 120.34% |
| Total Debt Issued | 1,400.00% | 650.00% | 650.00% | 1,500.00% | 0.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -36.16% | -14.28% | 19.03% | 27,734.69% | 192.42% |
| Repurchase of Common Stock | -- | -- | -- | -4,815.44% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -378.00% | -- | -- | -- | 12,586.67% |
| Cash from Financing | -22.01% | 18.81% | 54.94% | 4,779.54% | 192.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.02% | -183.22% | -188.25% | 153.63% | 217.15% |